Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation

被引:48
作者
Rolf, C
Knie, U
Lemmnitz, G
Nieschlag, E
机构
[1] Univ Munster, Inst Reprod Med, D-48129 Munster, Germany
[2] Dr August Wolff GmbH, D-33611 Bielefeld, Germany
关键词
D O I
10.1046/j.1365-2265.2002.01529.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Transdermal testosterone gel treatment is an effective androgen substitution therapy with several advantages over conventional substitution therapies. Whereas side-effects due to overdosing of hypogonadal patients are unlikely, testosterone gel application without protection may cause severe side-effects in other subjects (partners, family members) by contamination. Therefore, the risk of testosterone transfer of a newly developed 2.5% testosterone gel preparation was evaluated. Design In two clinical randomized open single-centre studies on healthy male volunteers the percentage of testosterone remaining on the skin after gel application over time (n=12) and the possibility of a transfer of testosterone to another person (n=28) was evaluated. In the second study the endogenous testosterone production in the receiving subjects was suppressed by injecting 400 mg norethisterone enanthate (NETE). Results After 8 h approximately 60% of testosterone applied to the skin could be recovered. When the skin had been previously washed with water, only about 14% of applied testosterone could be recovered. After intense skin contact with a volunteer who had applied testosterone before on his forearm, no increase in testosterone serum levels could be found in NETE-suppressed men. Conclusion Although considerable amounts of testosterone remain on the intact skin for several hours after evaporation of the alcohol vehicle, contamination of a second, especially female or prepubertal, subject causing side-effects seems very unlikely.
引用
收藏
页码:637 / 641
页数:5
相关论文
共 18 条
[1]  
BALSPRATSCH M, 1986, LANCET, V2, P943
[2]   Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years [J].
Behre, HM ;
von Eckardstein, S ;
Kliesch, S ;
Nieschlag, E .
CLINICAL ENDOCRINOLOGY, 1999, 50 (05) :629-635
[3]   TESTOSTERONE REPLACEMENT WITH TRANSDERMAL THERAPEUTIC SYSTEMS - PHYSIOLOGICAL SERUM TESTOSTERONE AND ELEVATED DIHYDROTESTOSTERONE LEVELS [J].
CUNNINGHAM, GR ;
CORDERO, E ;
THORNBY, JI .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (17) :2525-2530
[4]  
DELANOE D, 1984, LANCET, V1, P276
[5]  
*GERM PHARM, 1990, MON TEST S
[6]  
Jordan W P Jr, 1997, Am J Contact Dermat, V8, P108
[7]   Potential of norethisterone enanthate for male contraception:: pharmacokinetics and suppression of pituitary and gonadal function [J].
Kamischke, A ;
Diebäcker, J ;
Nieschlag, E .
CLINICAL ENDOCRINOLOGY, 2000, 53 (03) :351-358
[8]  
MENCZEL E, 1989, PERCUTANEOUS ABSORPT, P121
[9]  
MOORE N, 1988, LANCET, V1, P468
[10]  
NIESCHLAG E, 2000, ANDROLOGY MALE REPRO, P311